Showing results (131-140 of 142) with videos related to
Sort By:
Pageof 15
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999D G Bostwick, D J Grignon, M E Hammond, et al.Journal of the National Cancer Institute|January 15, 1997
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610D J Grignon, R Caplan, F H Sarkar, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|August 8, 2001
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trialF R Khuri, E S Kim, J J Lee, et al.International Journal of Radiation Oncology, Biology, Physics|July 4, 2012
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neckJay S Cooper, Qiang Zhang, Thomas F Pajak, et al.Journal of the National Cancer Institute|April 6, 2006
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patientsFadlo R Khuri, J Jack Lee, Scott M Lippman, et al.The New England Journal of Medicine|May 7, 2004
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neckJay S Cooper, Thomas F Pajak, Arlene A Forastiere, et al.Cancer|February 1, 1978
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapseF H Kung, W L Nythan, J Cuttner, et al.International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancyAndy Trotti, Adam Garden, Padraig Warde, et al.Cancer|August 15, 1980
A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's diseaseM R Cooper, T F Pajak, N I Nissen, et al.Lancet (London, England)|September 5, 2006
Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysisJean Bourhis, Jens Overgaard, Hélène Audry, et al.Pageof 15